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The genetic alterations responsible for the develop-
ment of cutaneous lymphoma are largely unknown.
Chromosome region 9p21 contains a gene locus
encoding an inhibitor of cyclin-dependent kinase 4,
and heterozygous deletions of this tumor suppressor
gene (p16) have been shown in a variety of malig-
nant tumors. We studied 11 randomly selected cuta-
neous CD30-positive large cell lymphomas. Several
areas containing 20±50CD30-positive lymphocytes
were microdissected in each case and subjected to
single-step DNA extraction. Loss of heterozygosity
analysis was performed using polymorphic markers
at 9p21 (IFNA, D9S171, D9S169) and 17p13 (TP53).
Samples from normal cells apart from CD30-positive
lymphocytes, e.g., CD30-negative lymphohistiocytic
in®ltrates and normal epidermal layer, were also
obtained in all cases from the same slide for compar-
ison with the tumor samples. Expression of CD30
and T-lineage antigens (CD3, CD45Ro) was con-
®rmed in all cases. Immunohistochemical staining
for p16 and p53 was performed using the mono-
clonal antibodies sc-1661 and DO-7, respectively. Of
the 11 informative cases, seven (64%) exhibited loss
of heterozygosity at least for one marker at 9p21
(p16), whereas no allelic deletions were found for the
polymorphic marker at 17p13 (p53). On immuno-
histochemistry loss of the p16 protein was detected
in two of 11 cases. Nuclear staining for p53 protein
was found in four of 11 cases. Here, we provide the
®rst evidence of the involvement of the tumor sup-
pressor gene p16 in primary cutaneous large cell
lymphoma. Whether p16 deletion in these lympho-
mas is associated with disease progression and
whether this method could serve as an early marker
to detect lymphomas at an early stage needs to be
addressed in future studies. Key words: CD30/gene/
LOH/lymphoma/p16/p53. J Invest Dermatol 115:1104±
1107, 2000
T
he genetic alterations involved in the transformation
from benign cutaneous lymphoproliferation to pri-
mary cutaneous lymphoma have not yet been
characterized. One of the main problems is the
identi®cation of the malignant lymphocytes within an
epidermotropic in®ltrate; cell culture studies are still dif®cult to
achieve in most cases, are time consuming, and harbour the
problem of studying culture-associated epiphenomena. Morpholo-
gic criteria have been applied and immunohistochemical markers
have been widely used to de®ne a transformed lymphocyte. CD30
is a molecule that identi®es activated T or B cells, Reed-Sternberg
cells, and lymphoid blasts. CD30-positive primary cutaneous large
T cell lymphomas (LCL) consist of large tumor cells, the majority
of which express the CD30 antigen. These lymphomas occur in
adults, and infrequently in children and adolescents. Most cases
show solitary or localized nodules or tumors (Willemze et al, 1997;
Kempf et al, 1999). Using a microdissection-based approach it has
become possible to retrieve single tumor cells or clusters of tumor
cells from immunohistochemically stained slides for genetic
analysis. CD30-positive LCL are especially suitable for applying
this technique, as they are characterized by sheets of large CD30-
positive blasts, allowing ``pure'' tumor cell populations to be
identi®ed and dissected.
The two most commonly altered genes in human cancer are p16
and p53 from the RB1 and the p53 pathway, respectively. Previous
studies have shown frequent deletions of the tumor suppressor gene
at 9p21 in T-acute lymphoblastic leukemia and diffuse large B cell
lymphoma (Gombart et al, 1994). We aimed to search for allelic
deletions of these tumor suppressor genes in primary cutaneous
CD30-positive LCL. In addition, an immunohistochemical analysis
using antibodies targeted against the p16 and p53 protein was
performed.
MATERIALS AND METHODS
Tumor samples Eleven randomly selected cutaneous CD30-positive
anaplastic LCL were studied. All specimens were primary untreated lesions
obtained from adults (six males, seven females, mean age 67.5 6 15 y).
Expression of CD30 and T-lineage antigens (CD3, CD45Ro) by LCL was
con®rmed in all cases using alkaline phosphatase-antialkaline phosphatase
(APAAP) techniques. CD30 was expressed by the majority (> 75% of
neoplastic cells) and met the criteria of CD30-positive lymphomas
(Kaudewitz et al, 1990; Kempf et al, 1999). In each case, paraf®n-
embedded hematoxylin and eosin and CD30-positive stained sections were
reviewed. Included were all cases showing large cell populations of CD30-
positive cell lineage.
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Microdissection From each section (n = 11) we microdissected between
50 and 100 CD30-positive lymphocytes. Microdissection was performed
under light microscope visualization (magni®cation 2003) using a 30-
gauge needle. Samples from normal cells apart from CD30-positive
lymphocytes, e.g., normal epidermal layer as well as CD30-negative areas
consisting of lymphohistiocytic in®ltrates devoid (or almost free) of tumor
cells, were also obtained in all cases from the same slide for comparison with
the tumor samples. Procured cells were immediately suspended in 30 ml of
buffer containing 0.05 M Tris-HCl, 1 mM ethylenediamine tetraacetic acid
(EDTA), 1% Tween 20, and 1 g per l proteinase K, pH 8.0, and incubated
2 d at 37°C. The mixture was boiled for 10 min at 94°C to inactivate
proteinase K, and 1.5 ml of this solution was used for polymerase chain
reaction (PCR). Analysis of loss of heterozygosity (LOH) was carried out
by PCR ampli®cation of microsatellite polymorphisms.
LOH analysis Three polymorphic DNA markers at chromosome 9p21
(IFNA, D9S171, D9S169), ¯anking the p16 gene, and one marker at
chromosome 17p13 (TP53) (Research Genetics, Huntsville, AL) were used
in this study. PCR was performed in 10 ml and contained 1 ml 10 3 PCR
buffer (Boehringer Mannheim, Germany), 50 pM of each primer, 20 nM
each of dCTP, dGTP, dTTP, dATP, 0.2 ml [32P]-dCTP (6000 Ci per
mmol), and 0.1 unit Taq DNA polymerase. Reactions were cycled in a
thermal cycler (Gene Amp PCR System 9600, Perkin Elmer, ZuÈrich,
Switzerland) and ampli®cation consisted of 35 cycles of 1 min at 94°C,
1 min at 60°C, and 1 min at 72°C with a ®nal 10 min extension at 72°C.
Labeled ampli®ed DNA was mixed with an equal volume of formamide
loading dye (95% formamide, 20 mM EDTA, 0.05% bromophenol blue,
and 0.05% xylene cyanol). The samples were denatured for 5 min at 94°C
and loaded onto a gel consisting of 6% acrylamide (49:1 acrylamide:bis).
Samples were electrophoresed at 1600 V for 2 h. Gels were transferred to
3 mm Whatman paper (Merck, Zurich, Switzerland), dried, and subjected
to autoradiography with Typon X-Ray DX 41 ®lm (Typon, Burgdorf,
Switzerland). A case was considered informative for a polymorphic marker
if normal tissue DNA showed two different alleles (heterozygosity). LOH
was de®ned as absence of or a greater than 80% reduction in the signal of
tumor allele compared with that of heterozyous normal allele.
Immunohistochemical analysis Immunohistochemical staining for
p53 was performed using a monoclonal antibody, D0-7 (Dako, Luzern,
Switzerland), that detects both mutant and wild-type p53 protein. The
staining was performed at a dilution of 1:10. The staining for p16 was
performed with the monoclonal mouse antibody sc-1661 (Santa Cruz,
Biotechnology), at a dilution of 1:50. The antibody reacts with p16 of
mouse, rat, and human origin. APAAP staining of tissue sections was
performed as previously described (Kamarashev et al, 1998). Brie¯y, tissue
sections 3±5 mm thick of formaldehyde-®xed and paraf®n-embedded tumor
specimens, adhered to slides coated with 0.1% (wt/vol) poly-1-lysine, were
deparaf®nized with xylene and rehydrated. Antigen retrieval was performed
by heating the slides placed in plastic cuvettes ®lled with EDTA buffer,
pH 8.0, initially for 2 min at 600 W and then three times for 5 min at
100 W. Non-speci®c binding sites were blocked by incubating slides with
normal rabbit serum for 15 min at room temperature. Tissue sections were
incubated with an excess of monoclonal antibodies for 60 min. This was
followed by three cycles of sequential incubations with rabbit antimouse
IgG xenoantibodies and APAAP complexes. The immunoreaction was
visualized with a developing solution (Dako). The percentage of stained
tumor cells in each tissue section was estimated independently by two
observers. Variations in the percentage of stained cells enumerated by the
two observers were within a 10% range. In the evaluation of p53 stain,
specimens with less than 5% positive tumor cells were judged as negative.
Positivity of over 5% of tumor cells was interpreted as overexpression.
Semiquantitative scoring was accomplished on the following scale: negative
(<5%), 1+ (5%±20%), 2+ (21%±50%), or 3+ (>50%). In most slides, the
nuclei of single basal layer keratinocytes were positive, a phenomenon that
has been reported previously and that provided an internal positive control.
The staining for p16 in the LCL was compared with that of normal
lymphoid tissue. Three tonsillae and one spleen specimen were taken as
controls.
RESULTS
Nine, six, four, and seven tumors were informative using the
polymorphic markers IFNA, D9S171, D9S169, and TP53,
respectively. Seven of 11 (64%) exhibited LOH at least for one
marker at 9p21 (p16), whereas no allelic deletions were found for
the polymorphic marker at 17p13 (p53) (Table I). None of the
CD30-negative areas in in®ltrates of LCL showed allelic loss. On
immunohistochemistry loss of the p16 protein was detected in two
of 11 cases. Nuclear staining for p53 protein was found in four of
11 cases (Table I, Fig 1).
DISCUSSION
In this study, we found allelic deletions within CD30-positive
lymphocytes in primary cutaneous CD30-positive LCL in seven of
11 cases (64%) using markers ¯anking the p16 tumor suppressor
gene. It is pertinent to note that all deletions were detected in the
CD30-positive areas with no deletions detected in the micro-
dissected CD30-negative areas, consisting of a lymphohistiocytic
in®ltrate devoid (or almost free) of tumor cells (Fig 1).
Loss or inactivation of tumor suppressor genes is important in the
development of many human cancers. Several previous studies have
addressed the frequency of p16/INK4A alterations in lymphoid
malignancies, and allelic deletions were found in T-acute
lymphoblastic leukemia and diffuse large B cell lymphoma
(Gombart et al, 1994). That p16 may be important in the formation
of at least some lymphoid malignant neoplasms is further supported
by the fact that p16 knockout mice have a high incidence of
lymphomas (Serrano et al, 1996). There is accumulating evidence
suggesting that the tumor suppressor gene p16 is targeted in most
tumors with deletions at 9p21 (Cairns et al, 1995). The majority of
Table I. Results of loss of heterozygosity (LOH) ± analysis for individual patientsa
LOH IH LOH IH
9p21 17q13
Case no. Age/sex Localisation IFNA D9S171 D9S169 p16 TP53 p53
1 71/m trunk NL LOH ± + NL ± (<1%)
2 55/f thigh NL ± ± + ± + (30%)
3 31/f cheek NL LOH ± + NL ± (<1%)
4 66/m bottom NL NL ± + NL ± (<1%)
5 98/f leg LOH LOH LOH ± ± ± (<5%)
6 76/m arm LOH LOH ± + NL ± {<1%)
7 72/m trunk LOH ± ± + ± + (<10%)
8 68/f trunk ± ± NL + ± ± (<1%)
9 68/f back LOH ± ± ± NL ± (<1%)
10 66/m back LOH LOH LOH + NL + (10%)
11 72/m arm ± ± NL + NL 1 (20%)
aAllelic deletions at 9p21 and 17q13 are given for the different markers, and related to the results of the immunohistochemical analysis (IH). LOH, loss of heterozygosity;
NL, no loss of heterozygosity; ±, noninformative (homozygous deletion).
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deletions involving the p16 region are homozygous and often
extend over 500 kb (Dreyling et al, 1995). It has been shown that
these deletions most often include the entire interferon gene
cluster, the p16 and p15 locus, the latter located approximately
25 kb centromeric from the p16 locus, as well as the methylthioa-
denosine phosporylase gene, located approximately 100 kb telo-
meric to p16 (Olopade et al, 1995). As no additional information
can be gained by the use of intragenic markers, we chose to use
¯anking markers of the p16 gene in our study.
Inactivation of the p16/INK4A gene has also been described as
arising due to de novo methylation at the 5¢CpG island, leading to
transcriptional blockage of p16 (Merlo et al, 1995). De novo
methylation at the 5¢CpG island, however, was not studied in our
specimens. The possibility of alternative mechanisms leading to the
formation of a tumor cell can thus not be excluded in the analyzed
samples.
In our study we detected loss of p16 protein on immunohis-
tochemistry in two of the 11 lesions studied (18%). In the literature
there are no data on the expression of p16 in CD30-positive
primary cutaneous lymphomas. According to the available data,
however, it seems that p16 loss is a frequent ®nding in nodal high
grade non-Hodgkin lymphomas (NHL), but not in their low grade
counterparts. Villuendas et al (1998) examined 112 NHL and found
loss of p16 expression in 41 tumors, all of which belonged to the
group of high grade lymphomas. Similarly Geradts et al (1998)
examined 101 NHL and reported p16 loss in 14 of the 55 high
grade lesions, but not in any of the low grade ones.
In our study immunohistochemistry revealed overexpression of
p53 in four of 11 specimens (36%). No allelic deletions of the
tumor suppressor gene p53 were demonstrated. This suggests that
the overexpression of p53 protein occurs through an alternative
mechanism. Our immunohistochemical results are compatible with
those of Van Haselen et al (1997), who detected overexpression of
p53 in six of 19 CD30+ lymphomas. Discrepancy between p53
gene mutation/deletion and p53 protein expression has also been
reported: Oka et al (1998) found an overexpression of p53 in 59 of
202 NHL but only four of these 59 cases showed a shift on single
strand conformation polymorphism analysis (SSCP) analysis, and
point mutations were detected in three of them by subsequent
sequencing. Cuoqing et al (1998) detected no mutations in six
specimens from patients with cutaneous T cell lymphoma with
large cell transformation, in which overexpression of p53 protein
was present. These data support the hypothesis that the mechanism
of p53 protein overexpression is in the majority of cases different
from gene mutation and/or allelic deletion.
The combined use of microdissection and LOH is a powerful
tool for analysing cutaneous lymphoma. The high frequency of
Figure 1. Results of LOH analysis. CD30+ (arrows) and CD30-
(arrowheads) areas, prior (a) and after (b) microdissection. (c) Sequence gel
analysis results obtained after subjection of microdissected cells to single-
step DNA extraction and ampli®cation using the primers D9S171, IFNA,
D9S169, and TP53. Loss of an allele was scored as more than 80% reduction
of the band intensity (arrowhead). Lanes N, normal epidermal layer; lanes ±,
CD30-negative in®ltrates; lanes +, CD30-positive in®ltrates.
Figure 2. Immunohistochemistry. Immunohistochemical staining for
p16 (a) and p53 (b). The majority of lymphocytes show p16 protein
expression (a) and p53 protein expression (b). Scale bar: 30 mM.
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allelic deletions at 9p21 in LCL might not only be helpful as a
diagnostic tool in the detection of cutaneous lymphoma, but
possibly also serve as a prognostic marker, as has already been
suggested for high grade neoplasms and lymphoid cell lines
(Villuendas et al, 1998).
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